Ubs Group Ag Candel Therapeutics, Inc. Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
A detailed history of Ubs Group Ag transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 9,446 shares of CADL stock, worth $40,239. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,446
Previous 6,005
57.3%
Holding current value
$40,239
Previous $37,000
75.68%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding CADL
# of Institutions
57Shares Held
6.43MCall Options Held
109KPut Options Held
130K-
Northpond Ventures, LLC1.94MShares$8.24 Million48.35% of portfolio
-
Vanguard Group Inc Valley Forge, PA946KShares$4.03 Million0.0% of portfolio
-
Black Rock Inc. New York, NY823KShares$3.51 Million0.0% of portfolio
-
State Street Corp Boston, MA492KShares$2.1 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA449KShares$1.91 Million0.0% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $123M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...